Indian drug companies must focus on new technologies, including development of "super-generics," in order to grow and flourish, said Andrew Barrett, director of medical technology in India at Cambridge Consultants. "[T]he required investments can be recouped because medical products have long lifecycles," he added. Other experts at a Mumbai conference noted that the biggest growth opportunities will come from innovations to differentiate products, because the number of expiring drug patents has peaked, and other countries are offering greater competition for low-cost generics.

Full Story:
PharmaTimes (U.K.)

Related Summaries